Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
Zsófia D. Drobni, Amna Zafar, Leyre Zubiri, et al.
Journal of the American Heart Association (2020) Vol. 9, Iss. 23
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Cardiovascular complications of immune checkpoint inhibitors for cancer
Franck Thuny, Jarushka Naidoo, Tomas G. Neilan
European Heart Journal (2022) Vol. 43, Iss. 42, pp. 4458-4468
Open Access | Times Cited: 75
Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: New insights for a potential predictor of anti-cytokine therapy responsiveness
Artemio García‐Escobar, Silvio Vera‐Vera, Daniel Tébar Márquez, et al.
Microvascular Research (2023) Vol. 150, pp. 104598-104598
Closed Access | Times Cited: 47
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Íñigo Les, Mireia Martínez, Inés Pérez-Francisco, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1629-1629
Open Access | Times Cited: 45
Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
David Jungpa Lee, Howard J. Lee, Jocelyn R. Farmer, et al.
Current Cardiology Reports (2021) Vol. 23, Iss. 8
Closed Access | Times Cited: 59
Pericardial disease in patients treated with immune checkpoint inhibitors
Jingyi Gong, Zsófia D. Drobni, Amna Zafar, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002771-e002771
Open Access | Times Cited: 57
Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Wei Zhang, Yifei Tan, Yuquan Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
Ben Ponvilawan, Abdul Wali Khan, Janakiraman Subramanian, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1225-1225
Open Access | Times Cited: 11
Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors
Tamás G. Gergely, Zsófia D. Drobni, Nabil V. Sayour, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 9
Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
Xinqing Lin, Haiyi Deng, Yilin Yang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 47
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
Emanuel Raschi, Simone Rossi, Andrea De Giglio, et al.
Drug Safety (2023) Vol. 46, Iss. 9, pp. 819-833
Open Access | Times Cited: 18
The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
Cho‐Han Chiang, Cho‐Hung Chiang, Kevin Sheng‐Kai, et al.
Japanese Journal of Clinical Oncology (2022) Vol. 52, Iss. 12, pp. 1389-1398
Open Access | Times Cited: 24
Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
Yi Zheng, Ziliang Chen, Wenhua Song, et al.
Cancer Medicine (2024) Vol. 13, Iss. 10
Open Access | Times Cited: 5
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments
Yuequan Shi, Xiaoyan Liu, Jia Liu, et al.
Translational Lung Cancer Research (2021) Vol. 10, Iss. 12, pp. 4477-4493
Open Access | Times Cited: 29
Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
Xiaohong Xie, Liqiang Wang, Ying-Qing Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
Advances in immune checkpoint inhibitors induced-cardiotoxicity
Xiang Li, Wenying Peng, Jiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
Lin Liang, Chanjuan Cui, Dan Lv, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 3, pp. 1907-1918
Open Access | Times Cited: 11
Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human
Jingyi Gong, Tomas G. Neilan, Daniel A. Zlotoff
Immunological Reviews (2023) Vol. 318, Iss. 1, pp. 70-80
Closed Access | Times Cited: 11
Risk factors associated with immune-related severe adverse events: A scoping review
Zhenzhen Su, Liyan Zhang, Xuemin Lian, et al.
Asia-Pacific Journal of Oncology Nursing (2025) Vol. 12, pp. 100661-100661
Open Access
Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer
Xue Jian, Chuanbin Liu, Jun Shao, et al.
Cancer Innovation (2025) Vol. 4, Iss. 2
Open Access
Immune checkpoint inhibitor-associated myocarditis: a review of current state of knowledge
Keila C Ostos-Mendoza, Valeria Saraiba-Rabanales, Paola Gutierrez-Gallegos, et al.
The Journal of Cardiovascular Aging (2025) Vol. 5, Iss. 1
Open Access
Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors
Alan H. Baik, Katy K. Tsai, David Y. Oh, et al.
Clinical Science (2021) Vol. 135, Iss. 5, pp. 703-724
Open Access | Times Cited: 24
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Daniel Rönen, Aseel Bsoul, Michal Lotem, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 540-540
Open Access | Times Cited: 18
Gut microbiota shed new light on the management of immune‐related adverse events
Bei Tan, Yun‐xin Liu, Hao Tang, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 19, pp. 2681-2691
Open Access | Times Cited: 17
Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis
Hongrui Lu, Pengfei Zhu, Ya-Ya Deng, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 5, pp. 1106-1116
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top